Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management (Q30249553)

13 June 2017

1 reference

title

Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management (English)

1 reference

Erratum to: Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management

13 June 2017

1 reference

1 reference

1 reference

1 reference

corrigendum / erratum

0 references

2

Susan H Fox

1 reference

13 June 2017

Anna Chang

1

1 reference

13 June 2017

16 June 2016

1 reference

13 June 2017

1 reference

13 June 2017

76

1 reference

13 June 2017

11

1 reference

13 June 2017

1093-1118

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-016-0600-5

13 June 2017

0 references

cites work

Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Scales to assess psychosis in Parkinson's disease: Critique and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Prospective longitudinal assessment of hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: II. Representative profile patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Positive and negative symptoms in the psychoses: principal components analysis of items from the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Prospective study of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

How common are complications of Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Psychiatric comorbidities in patients with Parkinson disease and psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Association between family history of dementia and hallucinations in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Prevalence of psychotic symptoms in a community-based Parkinson disease sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Epidemiology of psychosis in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Hallucinations in Parkinson's disease: a follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

A 12-year population-based study of psychosis in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Course of psychiatric symptoms and global cognition in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Psychiatric Side Effects of Levodopa in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Factors associated with drug-induced visual hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Hallucinations in Parkinson disease in the prelevodopa era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Feeling of presence in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Visual hallucinations in Parkinson's disease: a review and phenomenological survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

A preliminary investigation of laterality in Parkinson's disease and susceptibility to psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Early dopaminergic drug-induced hallucinations in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Hallucinations and sleep disorders in PD: six-year prospective longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Rate of clinical progression in Parkinson's disease. A prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Motor patterns in Parkinson's disease: a data-driven approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

A 12-year population-based study of freezing of gait in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Body side and predominant motor features at the onset of Parkinson's disease are linked to motor and nonmotor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Relationship of dementia and visual hallucinations in tremor and non-tremor dominant Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Hallucinations, dreaming, and frequent dozing in Parkinson disease: impact of right-hemisphere neural networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Parkin disease: a phenotypic study of a large case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

A multidisciplinary study of patients with early-onset PD with and without parkin mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Genomic investigation of alpha-synuclein multiplication and parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

LRRK2 G2019S mutation in Parkinson's disease: a neuropsychological and neuropsychiatric study in a large Algerian cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Psychiatric issues in cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Risk factors for hallucinations in Parkinson's disease: results from a large prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Visual symptoms in Parkinson's disease and Parkinson's disease dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The epidemiology of dementia associated with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The rate of cognitive decline in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Cognitive correlates of visual hallucinations in non-demented Parkinson's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Executive functions are impaired in patients with Parkinson's disease with visual hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Neuropsychological deficits in Parkinson's disease patients with visual hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Cognitive impairment patterns in Parkinson's disease with visual hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson's disease: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Cognitive correlates of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Isolated delusional syndrome in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Risk factors for visual hallucinations in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Hallucinations and sleep-wake cycle in PD: a 24-hour continuous polysomnographic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson's disease over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Features associated with the development of hallucinations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

REM behavior disorder, hallucinations and cognitive impairment in Parkinson's disease: a two-year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson's disease: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Retinal nerve fiber layer thickness and visual hallucinations in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Development of a prediction formula of Parkinson disease severity by optical coherence tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Are patients with Parkinson's disease blind to blindsight?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Lateral geniculate atrophy in Parkinson's with visual hallucination: A trans-synaptic degeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Visual hallucinations associated with Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Auditory hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Odor identification deficits identify Parkinson's disease patients with poor cognitive performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Hospitalisation and comorbidities in Parkinson's disease: a large Australian retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The interface between delirium and dementia in elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Review of delirium in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Time-course of cytokines during delirium in elderly patients with hip fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

At the extreme end of the psychoneuroimmunological spectrum: delirium as a maladaptive sickness behaviour response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Delirium in elderly people

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Separate visual pathways for perception and action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Integration of auditory and visual information about objects in superior temporal sulcus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Medial temporal regional argyrophilic grain as a possible important factor affecting dementia in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Cerebral atrophy in Parkinson's disease patients with visual hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Regional cortical grey matter loss in Parkinson's disease without dementia is independent from visual hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Cortical and subcortical brain atrophy in Parkinson's disease with visual hallucination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Visual hallucination in Parkinson's disease with FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Metabolic alterations in patients with Parkinson disease and visual hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Medication-induced hallucination and cerebral blood flow in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Caudate dopaminergic denervation and visual hallucinations: evidence from a ¹²³I-FP-CIT SPECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Preliminary FMRI evidence of visual system dysfunction in Parkinson's disease patients with visual hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The default mode network is disrupted in Parkinson's disease with visual hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Resting activity in visual and corticostriatal pathways in Parkinson's disease with hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Multimodal MRI of the hippocampus in Parkinson's disease with visual hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Visual loss in Alzheimer's disease: out of sight, out of mind.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Levodopa-induced psychosis: a kindling phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The dopamine hypothesis of schizophrenia: focus on the dopamine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The functional anatomy of basal ganglia disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Recent advances in the molecular biology of dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Structure and function of dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Targeting the dopamine D2 receptor in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The dopamine D4 receptor: biochemical and signalling properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The dopamine D(4) receptor: one decade of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Dopamine receptors - IUPHAR Review 13

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Long-term outcome of clozapine use for psychosis in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Serotonin 2A receptors and visual hallucinations in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Monoamines in the human neostriatum: Topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Reality monitoring and visual hallucinations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Altered cortical visual processing in PD with hallucinations: an fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Testing an aetiological model of visual hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Visual Priming and Visual Hallucinations in Parkinson's Disease. Evidence for Normal Top-Down Processes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Parkinson disease psychosis: Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

An update expert opinion on management and research strategies in Parkinson's disease psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Risperidone and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Olanzapine treatment for dopaminergic-induced hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Atypical antipsychotic drugs in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

What predicts mortality in Parkinson disease?: a prospective population-based long-term study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Current use of clozapine in Parkinson disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Melperone is ineffective in treating Parkinson's disease psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Newer antipsychotics and upcoming molecules for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

[Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Pharmacotoxic psychosis after memantine in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Mirtazapine improves visual hallucinations in Parkinson's disease: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

A Case of Parkinson Disease With Both Visual Hallucination and Pain Improved by Gabapentin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Quantitative evaluation of electroconvulsive therapy for Parkinson's disease with refractory psychiatric symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Electroconvulsive therapy in movement disorders: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0600-5

Relationship between age and subtypes of psychotic symptoms in Parkinson's disease

21 January 2018

1 reference

12 December 2020

Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations.

1 reference

12 December 2020

Pharmacology of hallucinations induced by long-term drug therapy

1 reference

12 December 2020

Yokukansan and its ingredients as possible treatment options for schizophrenia

1 reference

12 December 2020

Exacerbation of Lewy bodies dementia due to memantine.

1 reference

12 December 2020

The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation

1 reference

12 December 2020

Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons

1 reference

12 December 2020

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

12 December 2020

Visual hallucinations and cognitive impairment in Parkinson's disease.

1 reference

12 December 2020

The occurrence, distribution and physiological role of catecholamines in the nervous system

1 reference

12 December 2020

Proton Magnetic Resonance Spectroscopy Changes in Parkinson's Disease With and Without Psychosis.

1 reference

12 December 2020

Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system

1 reference

12 December 2020

Schizophrenia as a prodromal symptom in a patient harboring SNCA duplication

1 reference

12 December 2020

Demonstration and mapping of central neurons containing dopamine, noradrenaline, and 5-hydroxytryptamine and their reactions to psychopharmaca

1 reference

12 December 2020

Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action

1 reference

12 December 2020

Atypical antipsychotics: mechanism of action.

1 reference

12 December 2020

Ophthalmologic features of Parkinson's disease

1 reference

12 December 2020

LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample

1 reference

12 December 2020

Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening.

1 reference

12 December 2020

Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis

1 reference

12 December 2020

Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease.

1 reference

12 December 2020

Reduction of parkinsonism and psychosis with mirtazapine: a case report

1 reference

12 December 2020

Visual object recognition and attention in Parkinson's disease patients with visual hallucinations.

1 reference

12 December 2020

Unraveling multisensory integration: patchy organization within human STS multisensory cortex

1 reference

12 December 2020

Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease.

1 reference

12 December 2020

Location of human face-selective cortex with respect to retinotopic areas.

1 reference

12 December 2020

1 reference

12 December 2020

Motor and non-motor symptoms of 1453 patients with Parkinson's disease: prevalence and risks

1 reference

12 December 2020

MRI correlates of Parkinson's disease progression: a voxel based morphometry study

1 reference

12 December 2020

Nitric oxide and peroxynitrite serum levels in Parkinson's disease: correlation of oxidative stress and the severity of the disease

1 reference

12 December 2020

All-cause mortality associated with atypical and typical antipsychotics in demented outpatients

1 reference

12 December 2020

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

1 reference

12 December 2020

Dopamine agonist therapy in early Parkinson's disease

1 reference

12 December 2020

Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease

1 reference

12 December 2020

Prominent psychiatric symptoms in patients with Parkinson's disease and concomitant argyrophilic grain disease

1 reference

12 December 2020

Relation of clinical subtypes in Parkinson's disease with survival

1 reference

12 December 2020

The association of serum anticholinergic activity with delirium in elderly medical patients

1 reference

12 December 2020

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

1 reference

12 December 2020

Structural brain abnormalities in patients with Parkinson's disease with visual hallucinations: a comparative voxel-based analysis

1 reference

12 December 2020

α-synuclein in the inner retina in parkinson disease

1 reference

12 December 2020

Impact of standard of care for psychosis in Parkinson disease

1 reference

12 December 2020

Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease

1 reference

12 December 2020

Non-dipping nocturnal blood pressure and psychosis parameters in Parkinson disease

1 reference

12 December 2020

Clinical evaluation of Parkinson's disease dementia: association with aging and visual hallucination

1 reference

12 December 2020

Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations

1 reference

12 December 2020

Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis

1 reference

12 December 2020

Dopaminergic hallucinosis with fluoxetine in Parkinson's disease

1 reference

12 December 2020

Hallucinations in Parkinson's disease. prevalence, phenomenology and risk factors. Fenelon G* mahieux F, huon R, Ziegler M. Brain 2000;123:733-745

1 reference

12 December 2020

1 reference

12 December 2020

Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease

1 reference

12 December 2020

Serotonergically active agents in levodopa-induced psychiatric toxicity reactions.

1 reference

12 December 2020

Poor visual discrimination and visual hallucinations in Parkinson's disease

1 reference

12 December 2020

Antidepressants and psychosis in Parkinson disease: a case series

1 reference

12 December 2020

Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine

1 reference

12 December 2020

Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group

1 reference

12 December 2020

Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment.

1 reference

12 December 2020

Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia

1 reference

12 December 2020

Dopamine receptors: from structure to function

1 reference

12 December 2020

Fifty Percent Prevalence of Extracampine Hallucinations in Parkinson's Disease Patients

1 reference

12 December 2020

1 reference

12 December 2020

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values

1 reference

12 December 2020

Risperidone in Parkinson's disease

1 reference

12 December 2020

The role of acetylcholine and dopamine in dementia and psychosis in Parkinson's disease

1 reference

12 December 2020

Preclinical pharmacology of neuroleptics: focus on new generation compounds.

1 reference

12 December 2020

The malignant course of "benign hallucinations" in Parkinson disease

1 reference

12 December 2020

NOSIE-30: A Treatment-Sensitive Ward Behavior Scale

1 reference

12 December 2020

Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.

1 reference

12 December 2020

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease

1 reference

12 December 2020

10.1007/S40265-016-0600-5

Identifiers

DOI

1 reference

PubMed ID

27312429

Dimensions Publication ID

13 June 2017

0 references

1 reference

PubMed ID

27312429